Frontiers in Behavioral Neuroscience (Oct 2021)
Puerarin Alleviates Vascular Cognitive Impairment in Vascular Dementia Rats
- Tiantian Zhu,
- Tiantian Zhu,
- Tiantian Zhu,
- Moli Zhu,
- Moli Zhu,
- Moli Zhu,
- Yue Qiu,
- Yue Qiu,
- Yue Qiu,
- Zeqing Wu,
- Zeqing Wu,
- Zeqing Wu,
- Ning Huang,
- Ning Huang,
- Ning Huang,
- Guangrui Wan,
- Guangrui Wan,
- Guangrui Wan,
- Jian Xu,
- Jian Xu,
- Jian Xu,
- Ping Song,
- Ping Song,
- Ping Song,
- Shuangxi Wang,
- Shuangxi Wang,
- Shuangxi Wang,
- Yaling Yin,
- Yaling Yin,
- Yaling Yin,
- Peng Li,
- Peng Li,
- Peng Li
Affiliations
- Tiantian Zhu
- College of Pharmacy, Xinxiang Medical University, Xinxiang, China
- Tiantian Zhu
- Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China
- Tiantian Zhu
- Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China
- Moli Zhu
- College of Pharmacy, Xinxiang Medical University, Xinxiang, China
- Moli Zhu
- Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China
- Moli Zhu
- Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China
- Yue Qiu
- College of Pharmacy, Xinxiang Medical University, Xinxiang, China
- Yue Qiu
- Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China
- Yue Qiu
- Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China
- Zeqing Wu
- College of Pharmacy, Xinxiang Medical University, Xinxiang, China
- Zeqing Wu
- Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China
- Zeqing Wu
- Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China
- Ning Huang
- College of Pharmacy, Xinxiang Medical University, Xinxiang, China
- Ning Huang
- Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China
- Ning Huang
- Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China
- Guangrui Wan
- College of Pharmacy, Xinxiang Medical University, Xinxiang, China
- Guangrui Wan
- Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China
- Guangrui Wan
- Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China
- Jian Xu
- College of Pharmacy, Xinxiang Medical University, Xinxiang, China
- Jian Xu
- Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China
- Jian Xu
- Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China
- Ping Song
- College of Pharmacy, Xinxiang Medical University, Xinxiang, China
- Ping Song
- Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China
- Ping Song
- Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China
- Shuangxi Wang
- College of Pharmacy, Xinxiang Medical University, Xinxiang, China
- Shuangxi Wang
- Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China
- Shuangxi Wang
- Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China
- Yaling Yin
- Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China
- Yaling Yin
- Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China
- Yaling Yin
- School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, China
- Peng Li
- College of Pharmacy, Xinxiang Medical University, Xinxiang, China
- Peng Li
- Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, China
- Peng Li
- Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China
- DOI
- https://doi.org/10.3389/fnbeh.2021.717008
- Journal volume & issue
-
Vol. 15
Abstract
Cerebral ischemia triggers vascular dementia (VD), which is characterized by memory loss, cognitive deficits, and vascular injury in the brain. Puerarin (Pur) represents the major isoflavone glycoside of Radix Puerariae, with verified neuroprotective activity and cardiovascular protective effects. However, whether Pur ameliorates cognitive impairment and vascular injury in rats with permanent occlusion of bilateral common carotid arteries (BCCAO) remains unknown. This work aimed to assess Pur’s effects on BCCAO-induced VD and to dissect the underlying mechanisms, especially examining the function of transient receptor potential melastatin-related 2 (TRPM2) in alleviating cognitive deficits and vascular injuries. Rats with BCCAO developed VD. Pur (50, 100, and 150 mg/kg) dose-dependently attenuated the pathological changes, increased synaptic structural plasticity in the dorsal CA1 hippocampal region and decreased oxidative stress, which eventually reduced cognitive impairment and vascular injury in BCCAO rats. Notably, Pur-improved neuronal cell loss, synaptic structural plasticity, and endothelial vasorelaxation function might be mediated by the reactive oxygen species (ROS)-dependent TRPM2/NMDAR pathway, evidenced by decreased levels of ROS, malondialdehyde (MDA), Bax, Bax/Bcl2, and TRPM2, and increased levels of superoxide dismutase (SOD), Bcl2, and NR2A. In conclusion, Pur has therapeutic potential for VD, alleviating neuronal cell apoptosis and vascular injury, which may be related to the ROS-dependent TRPM2/NMDAR pathway.
Keywords
